Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03923920 · ClinicalTrials.gov registry record
Screening for Systemic Amyloidosis Via the Ligamentum Flavum
A clinical trial of Amyloidosis and Spinal Stenosis, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- 200
- Enrollment target
- 1
- Study location
NCT03923920: Completed study of Amyloidosis and Spinal Stenosis, sponsored by The Cleveland Clinic.
NCT03923920 is a study of Amyloidosis and Spinal Stenosis that has completed, run by The Cleveland Clinic. The registered enrollment target is 200 participants, below the 1,122-participant average among 28 other Amyloidosis trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03923920, a study of Amyloidosis and Spinal Stenosis, has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators will prospectively evaluate for the presence of amyloid deposits in ligamentum flavum (yellow ligament) tissue samples obtained from patients undergoing spinal stenosis surgery. Patients who have tissue that stains positive for amyloid will be referred to an amyloidosis specialist.
Primary Outcome
Incidence of amyloid deposits in removed ligamentum flavum tissue of older patients undergoing spinal stenosis surgery
Conditions Studied
Interventions
- PROCEDURE Biopsy
Study Locations (1)
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2019-05-01 |
| Est. Completion | 2021-12-02 |
What the finished NCT03923920 record still lists
NCT03923920 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 1,122-participant average among 28 other Amyloidosis trials with a reported enrollment target (82% lower).
The record links to 5 conditions, with Amyloidosis appearing as the primary indexed condition, and to 1 intervention - of which Biopsy is the first listed.
NCT03923920 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT03923920 about?
NCT03923920 is a clinical study titled "Screening for Systemic Amyloidosis Via the Ligamentum Flavum". The investigators will prospectively evaluate for the presence of amyloid deposits in ligamentum flavum (yellow ligament) tissue samples obtained from patients undergoing spinal stenosis surgery. Patients who have tissue that stains positive for amyloid will be referred to an amyloidosis specialist.
What is the current status of trial NCT03923920?
This trial is currently completed. The enrollment target is 200 participants. The study started on 2019-05-01. Estimated completion is 2021-12-02.
What conditions does trial NCT03923920 study?
This clinical trial studies the following conditions: Amyloidosis, Spinal Stenosis, Transthyretin Amyloidosis, Amyloid, Primary Amyloidosis of Light Chain Type.
What interventions are being tested in trial NCT03923920?
The interventions under investigation include: Biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT03923920?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03923920 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyloidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03923920's enrollment target sits among peer trials
200 11th of 28 higher than 18 of 28 other Amyloidosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Amyloidosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis
RECRUITING · Phase 2
-
Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry
RECRUITING
-
A Study Of Myocardial Stiffness In Amyloidosis With Magnetic Resonance Elastography
RECRUITING
-
Dietary Reporting in the Amyloidoses
RECRUITING · NA
-
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
RECRUITING · Phase 1
-
Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI